Prenetics Global (Prenetics Global) Expense Ratio % : 26.20% (As of Jun. 2019)

View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global Expense Ratio %?

Expense Ratio % is the percentage of expenses associated with acquiring, underwriting, and servicing premiums to net premium earned. It indicates the efficiency of the insurance company before considering its claims and investment gains or losses.

Prenetics Global's Expense Ratio % for the quarter that ended in Jun. 2019 was 26.20% , which is lower than 28.30% for the pervious quarter ended in Jun. 2018.

The historical rank and industry rank for Prenetics Global's Expense Ratio % or its related term are showing as below:

PRE's Expense Ratio % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median:
* Ranked among companies with meaningful Expense Ratio % only.

Prenetics Global Expense Ratio % Historical Data

The historical data trend for Prenetics Global's Expense Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global Expense Ratio % Chart

Prenetics GlobalQuarterly Data

Trend

Jun17

Sep17

Mar18

Jun18

Jun19

Expense Ratio %

Get a 7-Day Free Trial

Combined Ratio %

Get a 7-Day Free Trial

Claims Ratio %

Get a 7-Day Free Trial

Competitive Comparison of Prenetics Global's Expense Ratio %

For the Diagnostics & Research subindustry, Prenetics Global's Expense Ratio %, along with its competitors' market caps and Expense Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prenetics Global (NAS:PRE) Expense Ratio % Calculation

Expense Ratio % is calculated as:

Expense Ratio %

Expenses of Acquiring, Underwriting and Servicing Premiums

Net Premium Earned

100%

Prenetics Global (NAS:PRE) Expense Ratio % Explanation

Expense Ratio % is the percentage of expenses associated with acquiring, underwriting, and servicing premiums to net premium earned. It can be used to make comparisons between insurance companies as well as measure their performance. An expense ratio below 100% suggests that the premiums an insurance company earned or wrote are more than the expenses it paid to support those premiums.

However, we should keep in mind that the ratio does not indicate an ending profitability. The overall profit is also influenced by the claims, investment gains or losses and other income. The ratio can be combined with Claims Ratio % and Combined Ratio % to get an overall performance of an insurance company.

Prenetics Global Expense Ratio % Related Terms

Thank you for viewing the detailed overview of Prenetics Global's Expense Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prenetics Global (Prenetics Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » Expense Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG

Website

https://www.prenetics.com

Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.